Introduction {#sec1-1}
============

Pyoderma gangrenosum (PG), an uncommon neutrophilic dermatosis, presents as an inflammatory papule or pustule and progresses rapidly to form a painful ulcer with violaceous undermined borders. PG can be either idiopathic or associated with underlying systemic conditions, particularly inflammatory bowel disease (IBD), such as Crohn\'s disease and ulcerative colitis (UC). The pathogenesis of the lesion is not fully understood, but it is thought be a multifactorial combination with neutrophil dysfunction, cytokines dysregulation, and specific genetic mutation.\[[@ref1]\]

PG is a challenging cutaneous condition due to the lack of validated diagnostic criteria and evidence-based therapies.\[[@ref2]\] As the incidence of PG is low, treatment options are mainly based on expert opinion, anecdotal data from case reports, retrospective cohort studies. A review of the literature based on \>350 PG patients demonstrated therapeutic efficacy of systemic corticosteroids or cyclosporine alone or together and recommended that they should be considered as the first-line therapy.\[[@ref3]\] Patients without response to standard treatment procedures should be administrated with other drugs, including intravenous immunoglobulins (IVIGs), dapsone, cyclophosphamide, azathioprine, tacrolimus, mycophenolate mofetil, and anti-TNFα therapy. Topical treatment may be sufficient for localized PG. However, another systematic review of IBD-associated PG,\[[@ref4]\] based on 60 cases, reported a low response rate for systemic corticosteroids (22%) and recommended anti-TNFα agents with the highest response rate (92%) as the first-line therapy.

The standard and effective therapy for IBD-associated PG is still controversial due to the paucity of case reports and RCTs. In this retrospective study, we reviewed a series of cases with the aim to provide evidence-based data on disease characteristics and treatment response in patients of PG concurrent with IBD.

Methods {#sec1-2}
=======

We retrospectively reviewed medical records of 42 IBD-associated PG patients who presented at our institution during the period from January 2007 to May 2018, and collected detailed clinical data, such as demographics, PG characteristics, subtype, and disease activity of IBD and specific therapies used and their treatment response. These data were obtained from chart review and recorded on a standard data collection sheet.

Given the small sample size, descriptive statistics were mainly used and analyses were exploratory in nature.

Results {#sec1-3}
=======

 {#sec2-1}

### Demographic characteristics of patients {#sec3-1}

The baseline and demographic characteristics of these 42 patients were summarized in [Table 1](#T1){ref-type="table"}. The majority were women (29) and 39 had UC (92.9%). Almost 23.8% of the sample were smokers at the time of inclusion. The ulcerative subtype of PG was observed in 32 cases, pustular subtype in 5 cases, peristomal subtype in 4 cases, and vegetative subtype in 1 case. Stoma were present in three patients with Crohn\'s disease and one patient with UC and only 14.3% were on IBD therapy at new PG onset (5-aminosalicylic acid and corticosteroids were the most frequently reported treatments). Other cutaneous manifestations were infrequently observed in patients, whereas joint involvement was more common affecting 19% of the sample.

###### 

Baseline and demographic characteristics of the patients included

  Variable                                  (*n*=42)
  ----------------------------------------- ------------
  Age (year)^†^                             40.5±14.6
  Sex                                       
   Female                                   29 (69.0%)
   Male                                     13 (31.0%)
  Smoker                                    10 (23.8%)
  Type of IBD                               
   Ulcerative colitis                       39 (92.9%)
   Crohn's disease                          3 (7.1%)
  Disease duration (year)^†^                5.6±3.4
  Presence of stoma                         4 (9.5%)
  Patients on IBD therapy at PG onset       6 (14.3%)
  Patients on no IBD therapy at PG onset    14 (33.3%)
  IBD therapy at PG onset was unspecified   22 (52.4%)
  Other cutaneous manifestations of IBD     4 (9.5%)
  Joint involvement                         8 (19.0%)

IBD: Inflammatory bowel disease, PG: Pyoderma gangrenosum. ^†^Mean±SD

### PG characteristics {#sec3-2}

PG ulcers were most frequently located on the legs and only a single ulcer or two were present in over half of those cases \[[Table 2](#T2){ref-type="table"}\]. PG was confirmed by biopsy in 31 cases and diagnosed with clinical manifestation without biopsy in 11 cases. In total, 39 patients had active IBD with clinical symptoms with or without blood test. Active IBD was confirmed by endoscopy in 29/39 patients with the activity classed as moderate in most cases. Three cases were in remission at the time of presentation of PG based on the absence of clinical manifestation with normal blood tests without endoscopy.

###### 

Characteristics of pyoderma gangrenosum

  Variable                                                        (*n*=42)
  --------------------------------------------------------------- ------------
  Site                                                            
   Legs                                                           14 (33.3%)
   Feet                                                           9 (21.4%)
   Abdomen                                                        5 (11.9%)
   Multiple sites                                                 6 (14.3%)
   Arm                                                            4 (9.5%)
   Genitals                                                       2 (4.8%)
   Peristomal                                                     2 (4.8%)
   Lesion size (cm)^§,†^                                          6.9±4.4
  Lesion number                                                   
   One ulcer                                                      16 (38.1%)
   Two ulcers                                                     15 (35.7%)
   Three ulcers                                                   5 (11.9%)
   More than three ulcers                                         6 (14.3%)
  Diagnosis of PG                                                 
   By biopsy                                                      31 (73.8%)
   By clinical manifestation without biopsy                       11 (26.2%)
   Time between onset of IBD and presentation of PG (year)^§,‡^   4.3±3.0
  IBD status at time of presentation of PG^¶^                     
   Remission                                                      3 (10.3%)
   Mildly active                                                  6 (20.7%)
   Moderately active                                              12 (41.4%)
   Severely active                                                8 (27.6%)

IBD: Inflammatory bowel disease, PG: Pyoderma gangrenosum, ^§^Mean±SD. ^†^*n*=32 (data unavailable for remaining patients), ^‡^*n*=35 (data unavailable for remaining patients), ^¶^N=29 (data unavailable for remaining patients)

### PG response to specific therapies {#sec3-3}

In this study, we concentrated on therapeutic efficacy only in patients with UC-associated PG, not in those with other IBD subtypes due to a very limited case numbers. The initial therapy for new onset PG was defined as " first-line" therapy. When first-line treatment failed to induce remission or complete healing, the subsequent therapy was defined as "second-line" therapy. The good response to a specific therapy was defined as clinical improvements of both skin lesions and luminal symptoms, in other words, a decrease \>50% in lesion size, in addition to a decrease/cease in mucopurulent bloody stool. All first-line therapies used; response rates and need for second-line therapies were summarized in [Table 3](#T3){ref-type="table"}.

###### 

Summary of all first-line therapies used, response rates, and need for second-line therapies in 39 ulcerative colitis associated pyoderma gangrenosum

  First-line therapies used           Number   Response   Second-line required
  ----------------------------------- -------- ---------- ----------------------
  Corticosteroids+5-ASA               17       16         1
  5-ASA alone                         7        3          4
  corticosteroids alone               5        5          0
  IVIG (alone or in combination)      4        4          0
  Infliximab (in combination)         3        3          0
  Cyclophosphamide (in combination)   3        3          0

5-ASA: 5-aminosalicylic acid, IVIG: Intravenous immunoglobulin

The combination of corticosteroids and 5-aminosalicylic acid (5-ASA) was the most frequently used therapy in patients with 17 receiving it as first line and three as second line. Encouragingly, a good response to the combination therapy was reported in 19/20 patients, with corticosteroid-dependent response in one case. The patient, who died with a severe complication of cerebral venous sinus thrombosis, was the only one that did not response to the combination therapy. It is worthwhile to note a case where a 26-week pregnant woman healed with the combination therapy and gave birth to a healthy baby without any drug-associated side effects.

Seven patients received monotherapy with 5-ASA and three had a good response. Of them, four cases did not respond and received second-line therapy with the addition of corticosteroids or cyclophosphamide alone or in combination for healing. Besides, five cases were healed with corticosteroids alone as first-line therapy.

IVIG was given to two patients as monotherapy and other two as combination therapy with all having a good response. Of the latter two patients, one was treated with IVIG + 5-ASA and the other with IVIG + 5-ASA + corticosteroids.

Infliximab together with other agents as combination therapy was given to three patients. One was administrated with 5-ASA and the other two with corticosteroids and 5-ASA in addition to infliximab. They were all successfully treated with no adverse effects.

Cyclophosphamide was usually used as adjuvant treatment and combined with corticosteroids and 5-ASA for severe or corticosteroid-dependent cases. Such combination therapy was adopted in three patients with a good response.

Discussion {#sec1-4}
==========

In this study, we retrospectively reviewed a large case series of IBD-associated PG in Chinese population. Some points to note include that the occurrence of PG was more common in females than in males. Interestingly, in our study, 39 cases (92.9%) had UC, although previous studies reported controversial results about the association between a particular IBD subtype and PG. A previous systematic review of 60 cases reported a similar PG occurrence in UC and Crohn\'s disease.\[[@ref4]\] However, in a large population-based Manitoba cohort, PG was more prevalent in patients with Crohn\'s disease.\[[@ref5]\] The correlation between PG and a specific IBD subtype seems to be affected by demographic characteristics, especially races. Traditionally, it was thought that PG onset and IBD activity followed independent courses. However, PG frequently occurred in patients with an established diagnosis of IBD and was concomitant with active luminal disease in this study. This result was consistent with the findings of a previous study,\[[@ref6]\] which revealed that 75% of patients with PG onset had active IBD disease. These findings indicate that the correlation between luminal disease activity and PG is stronger than previously reported.

Of all the therapies reported, the combination therapy of systemic corticosteroids and 5-ASA was the most commonly used one (*n* = 20) and appeared to be significantly effective in UC patients (95% response rate). This therapy was reported only in three cases in the literature and all showed a complete resolution.\[[@ref7][@ref8][@ref9]\] The efficacy of the combination therapy can be explained in two aspects. On the one hand, systemic corticosteroids was therapeutically effective and strongly recommended as first-line therapy for both PG\[[@ref10]\] and UC.\[[@ref11]\] In this study, good response to corticosteroids as first-line monotherapy was reported in 5/5 patients. On the other hand, 5-ASA was strongly recommended as first-line treatment in mild-to-moderate UC in clinical practice guidelines.\[[@ref11]\] The successful use of 5-ASA was observed in 3/7 UC patients in this study and 2/2 in the literature,\[[@ref12][@ref13]\] suggesting that it is possible that 5-ASA may play a direct role in remission of PG. Oka reported that 5-ASA could treat UC-associated PG via downregulation of IL-8 production from fibroblasts in the skin lesions.\[[@ref12]\] Another study reported that topical 5-ASA cream successfully treated PG via suppression of leukocyte motility and cytotoxicity.\[[@ref13]\] We cannot exclude the possibility that the improvement of PG is secondary to the improvement of UC and it is beneficial to control underlining UC activity for PG management.\[[@ref14]\] It appears that corticosteroids with therapeutic efficacy to both PG and UC might be a stone that can be used to kill two birds, and 5-ASA might have a similar dual effect. Thus, the combination of these two drugs is promising in the management of UC-associated PG and should be considered as the first-line therapy.

With respect to this complicated condition of PG patients with active UC, treatment regimen is directed to both PG and UC. Corticosteroids is a good choice due to its known therapeutic efficacy to both PG and UC separately. Five-ASA is also administrated due to digestive symptoms and its known association of PG with UC. That is why this combination therapy is most frequently used in our center, but it is hard to specify which treatment is more effective for which component of the association. When patients were separately administrated with corticosteroids or 5-ASA in our study, it seemed that corticosteroids were more effective than 5-ASA (5/5 vs. 3/7). More studies are required to investigate this issue.

We noted that first-line therapies with IVIG, infliximab, or cyclophosphamide were administered in a very limited number of UC-associated PG cases, most of which were treated in combination with corticosteroids and/or 5-ASA in our center. It is hard to determine to which therapy these patients responded, given the therapeutic efficacy of corticosteroids and 5-ASA in other cases. In this study, we provided little therapeutic evidence of IVIG, infliximab or cyclophosphamide in the management of UC-associated PG. Several studies had reported controversial results of first-line therapy with anti-TNF-α agents.\[[@ref4][@ref15]\] Studies comparing first-line therapy of anti-TNF-α agents with corticosteroids are needed to provide more solid evidence for clinical recommendation. Furthermore, cost may be a limiting factor for the option of anti-TNF-α or IVIG therapy in a developing country, such as China, and these treatments may be considered as second-line therapies.

There are several limitations of this study. First, the collection of standard information was not available due to the retrospective nature of this study. Second, the case number is unsurprisingly so limited, but given the rarity of this entity, we believe that it still provides valuable data of disease characteristics and treatment outcomes of PG complicating IBD. More studies are needed to further investigate the clinical characteristics and treatment strategies of this rare cutaneous condition. Third, recurrence data were unavailable, although such information would undoubtedly be useful.

Conclusion {#sec1-5}
==========

PG appears to be more prevalent in females and patients with UC in Chinese population. New PG occurrence is predominantly associated with active UC-related inflammatory activity and a re-evaluation of intestinal activity is needed. From the data reviewed here, corticosteroids in combination with 5-ASA may be considered as first-line therapy for UC-associated PG.
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